V Square Quantitative Management LLC Increases Stake in Bio-Techne Co.

Photo of author
Written By Faith Boluwatife

V Square Quantitative Management LLC recently boosted its position in shares of Bio-Techne Co. (NASDAQ) by 18.6% during the fourth quarter. According to the company’s latest Form 13F filing with the SEC, V Square Quantitative Management LLC acquired an additional 641 shares, bringing its total holdings to 4,094 shares valued at approximately $316,000.

Institutional Investment

Credits: DepositPhotos

Several other institutional investors and hedge funds have also been active in buying and selling shares of Bio-Techne. HighTower Advisors LLC increased its stake by 5.4% in the third quarter, now holding 18,866 shares worth $1.29 million after purchasing an additional 965 shares.

Meanwhile, DekaBank Deutsche Girozentrale boosted its stake by 2.5% in the same period, now owning 20,880 shares valued at $1.415 million after acquiring an additional 518 shares.

Kestra Advisory Services LLC significantly increased its position in Bio-Techne, adding 27,647 shares during the third quarter to hold a total of 32,766 shares valued at $2.23 million. Similarly, Rafferty Asset Management LLC grew its stake by 7.5%, now holding 16,426 shares worth $1.118 million.

Korea Investment CORP also raised its holdings by 75.8%, now owning 68,603 shares worth $4.67 million. Overall, 98.95% of Bio-Techne’s stock is owned by hedge funds and other institutional investors.

Analyst Ratings and Stock Performance

Bio-Techne has received various ratings from analysts recently. Deutsche Bank Aktiengesellschaft reduced its price target from $85.00 to $82.00 but maintained a “buy” rating.

Robert W. Baird raised their target price from $73.00 to $81.00, also giving the stock an “outperform” rating. Benchmark reiterated a “buy” rating with a price target of $95.00, while Citigroup downgraded the stock from a “buy” to a “neutral” rating, setting a price objective of $85.00.

Currently, the stock has an average rating of “Moderate Buy” and an average target price of $81.00 according to MarketBeat.com.

Bio-Techne’s stock opened at $75.87 on Monday. The firm’s 50-day moving average is $74.33, and its 200-day moving average is $72.60. Bio-Techne has a 52-week low of $51.79 and a 52-week high of $89.91.

The company has a market capitalization of $11.96 billion, with a P/E ratio of 60.21, a P/E/G ratio of 9.11, and a beta of 1.29. It has a debt-to-equity ratio of 0.19, a quick ratio of 2.88, and a current ratio of 4.08.

Recent Financial Results

Bio-Techne reported its latest earnings on May 1st, posting $0.48 earnings per share (EPS) for the quarter, exceeding analysts’ consensus estimate of $0.45 by $0.03. The company recorded revenue of $303.43 million for the quarter, surpassing the expected $292.36 million.

This marks a 3.2% increase in revenue compared to the same quarter last year. Bio-Techne’s return on equity stood at 13.60%, with a net margin of 17.59%. Analysts anticipate that Bio-Techne will post 1.56 EPS for the current fiscal year.

Dividend Information

Bio-Techne recently announced a quarterly dividend, which was paid on May 24th. Shareholders of record on May 13th received a dividend of $0.08 per share, equating to an annual dividend of $0.32 and a yield of 0.42%.

The ex-dividend date was May 10th. The company’s dividend payout ratio (DPR) is currently 25.40%.

About Bio-Techne

Bio-Techne Corporation, along with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets globally.

The company operates in the United States, the United Kingdom, Europe, the Middle East, Africa, Greater China, and the Asia-Pacific region.


Credits: DepositPhotos

Bio-Techne continues to attract significant institutional interest, with recent increases in holdings by various funds and positive analyst ratings. The company’s financial performance shows steady growth, and its stock remains a favorable option for investors.

With a strong market position and ongoing development in life science reagents and instruments, Bio-Techne is well-positioned for continued success in the biotechnology sector.




You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.